Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary R Cutter

Showing results (1-10 of 296) with videos related to

Pageof 30
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2012
Statistical cures and other fallaciesGary R Cutter
Multiple Sclerosis and Related Disorders|May 15, 2025
Critical issues in recommending extended interval dosingGary R Cutter
Nature Reviews. Neurology|December 17, 2016
Clinical trials: To catch a crook, you might try statisticsGary R Cutter
Neurology. Clinical Practice|May 2, 2013
Personalized medicine: The return of the house call?Gary R Cutter, Yuliang Liu
Neurology. Clinical Practice|November 1, 2013
Cost-effectiveness analyses: Beauty and the beast?Gary R Cutter, Guoqiao Wang
Neurology. Clinical Practice|July 1, 2015
To treat or not to treat, that really is not the questionGuoqiao Wang, Gary R Cutter
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 10, 2014
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?Gary R Cutter, Olaf Stüve
JAMA Neurology|July 1, 2014
Does natalizumab therapy benefit patients with multiple sclerosis?Olaf Stüve, Gary R Cutter
The Lancet. Neurology|April 6, 2015
Multiple sclerosis drugs: how much bang for the buck?Olaf Stüve, Gary R Cutter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 15, 2021
If Thymectomy Reduces the Risk of Progression of Ocular to Generalized Myasthenia Gravis, Who Should Receive it?Gary R Cutter, Donald B Sanders
Pageof 30

Showing results (1-10 of 296) with videos related to

Sort By:
Pageof 30
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2012
Statistical cures and other fallaciesGary R Cutter
Multiple Sclerosis and Related Disorders|May 15, 2025
Critical issues in recommending extended interval dosingGary R Cutter
Nature Reviews. Neurology|December 17, 2016
Clinical trials: To catch a crook, you might try statisticsGary R Cutter
Neurology. Clinical Practice|May 2, 2013
Personalized medicine: The return of the house call?Gary R Cutter, Yuliang Liu
Neurology. Clinical Practice|November 1, 2013
Cost-effectiveness analyses: Beauty and the beast?Gary R Cutter, Guoqiao Wang
Neurology. Clinical Practice|July 1, 2015
To treat or not to treat, that really is not the questionGuoqiao Wang, Gary R Cutter
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 10, 2014
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?Gary R Cutter, Olaf Stüve
JAMA Neurology|July 1, 2014
Does natalizumab therapy benefit patients with multiple sclerosis?Olaf Stüve, Gary R Cutter
The Lancet. Neurology|April 6, 2015
Multiple sclerosis drugs: how much bang for the buck?Olaf Stüve, Gary R Cutter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 15, 2021
If Thymectomy Reduces the Risk of Progression of Ocular to Generalized Myasthenia Gravis, Who Should Receive it?Gary R Cutter, Donald B Sanders
Pageof 30